Immuneering Slides As Insider Purchases Lose Another US$82k

The recent 10% drop in Immuneering Corporation's (NASDAQ:IMRX) stock could come as a blow to insiders who purchased US$478.0k worth of stock at an average buy price of US$2.43 over the past 12 months. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth US$396.1k which is not ideal.

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

Check out our latest analysis for Immuneering

The Last 12 Months Of Insider Transactions At Immuneering

The Director Peter Feinberg made the biggest insider purchase in the last 12 months. That single transaction was for US$183k worth of shares at a price of US$3.05 each. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$2.01). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.

While Immuneering insiders bought shares during the last year, they didn't sell. The average buy price was around US$2.43. This is nice to see since it implies that insiders might see value around current prices. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Immuneering is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Does Immuneering Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 29% of Immuneering shares, worth about US$19m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At Immuneering Tell Us?

The fact that there have been no Immuneering insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. Insiders do have a stake in Immuneering and their transactions don't cause us concern. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Immuneering. Case in point: We've spotted 6 warning signs for Immuneering you should be aware of, and 4 of these are potentially serious.

Of course Immuneering may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.